Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ROPEGINTERFERON ALFA-2B-NJFT: 1,405 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
1,405
Total FAERS Reports
17 (1.2%)
Deaths Reported
119
Hospitalizations
1,405
As Primary/Secondary Suspect
5
Life-Threatening
1
Disabilities
Prescription
Status

FDA Application: 761166 ·

First Report: 20191220 · Latest Report: 20250729

What Are the Most Common ROPEGINTERFERON ALFA-2B-NJFT Side Effects?

#1 Most Reported
Fatigue
298 reports (21.2%)
#2 Most Reported
Off label use
210 reports (14.9%)
#3 Most Reported
Pruritus
152 reports (10.8%)

All ROPEGINTERFERON ALFA-2B-NJFT Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Fatigue 298 21.2% 0 13
Off label use 210 15.0% 4 24
Pruritus 152 10.8% 0 9
Headache 135 9.6% 0 8
Inappropriate schedule of product administration 103 7.3% 0 9
Product dose omission issue 99 7.1% 1 7
Influenza like illness 97 6.9% 0 4
Nausea 91 6.5% 1 3
Diarrhoea 89 6.3% 0 11
Arthralgia 88 6.3% 0 10
Pain 82 5.8% 0 7
Platelet count increased 75 5.3% 0 6
Haematocrit increased 74 5.3% 0 3
Dizziness 70 5.0% 0 5
Injection site erythema 68 4.8% 0 4
Feeling abnormal 64 4.6% 0 7
Platelet count decreased 57 4.1% 1 1
Myalgia 55 3.9% 0 3
White blood cell count decreased 53 3.8% 0 1
Alopecia 52 3.7% 0 1

Who Reports ROPEGINTERFERON ALFA-2B-NJFT Side Effects? Age & Gender Data

Gender: 60.0% female, 40.0% male. Average age: 51.6 years. Most reports from: US. View detailed demographics →

Is ROPEGINTERFERON ALFA-2B-NJFT Getting Safer? Reports by Year

YearReportsDeathsHosp.
2019 1 0 0
2020 1 0 0
2021 10 1 2
2022 272 2 26
2023 296 4 29
2024 36 2 13
2025 21 2 10

View full timeline →

What Is ROPEGINTERFERON ALFA-2B-NJFT Used For?

IndicationReports
Polycythaemia vera 1,011
Product used for unknown indication 156
Essential thrombocythaemia 123
Myeloproliferative neoplasm 54
Polycythaemia 23
Cutaneous t-cell lymphoma 12
Myelofibrosis 8

ROPEGINTERFERON ALFA-2B-NJFT vs Alternatives: Which Is Safer?

ROPEGINTERFERON ALFA-2B-NJFT vs ROPINIROLE ROPEGINTERFERON ALFA-2B-NJFT vs ROPIVACAINE ROPEGINTERFERON ALFA-2B-NJFT vs ROSIGLITAZONE ROPEGINTERFERON ALFA-2B-NJFT vs ROSUVASTATIN ROPEGINTERFERON ALFA-2B-NJFT vs ROSUVASTATIN\ROSUVASTATIN ROPEGINTERFERON ALFA-2B-NJFT vs ROTIGOTINE ROPEGINTERFERON ALFA-2B-NJFT vs ROXADUSTAT ROPEGINTERFERON ALFA-2B-NJFT vs ROXICODONE ROPEGINTERFERON ALFA-2B-NJFT vs ROXITHROMYCIN ROPEGINTERFERON ALFA-2B-NJFT vs ROZANOLIXIZUMAB

Official FDA Label for ROPEGINTERFERON ALFA-2B-NJFT

Official prescribing information from the FDA-approved drug label.